Health-related quality-of-life analysis from the TRINOVA-1 study of weekly paclitaxel plus trebananib or placebo in women with recurrent ovarian cancer

Raspagliesi, Francesco

138 - Scientific Plenary
Health-related quality-of-life analysis from the TRINOVA-1 study of weekly paclitaxel plus trebananib or placebo in women with recurrent ovarian cancer

Tuesday, March 25, 2014: 7:58 AM

Ballroom B/C (Tampa Convention Center)

F. Raspagliesi¹, C. Lhommé², B. J. Monk³, R. L. Coleman⁴, T. J. Herzog⁵, L. Navale⁶, D. J. Warner⁶ and K. Fujiwara⁷
¹Fondazione IRCCS Istituto Nazionale Tumori -Milan, Milan, Italy, ²Institut Gustave Roussy, Villejuif, France, ³University of Arizona Cancer Center, Phoenix, AZ, ⁴The University of Texas MD Anderson Cancer Center, Houston, TX, ⁵Columbia University College of Physicians and Surgeons, New York, NY, ⁶Amgen Inc., Thousand Oaks, CA, ⁷Saitama Medical University International Medical Center, Hidaka-Shi, Japan

45th Annual Meeting on Women's Cancer

March 21 - 25, 2014

Navigation

138 - Scientific Plenary
Health-related quality-of-life analysis from the TRINOVA-1 study of weekly paclitaxel plus trebananib or placebo in women with recurrent ovarian cancer

138 - Scientific Plenary Health-related quality-of-life analysis from the TRINOVA-1 study of weekly paclitaxel plus trebananib or placebo in women with recurrent ovarian cancer

138 - Scientific Plenary
Health-related quality-of-life analysis from the TRINOVA-1 study of weekly paclitaxel plus trebananib or placebo in women with recurrent ovarian cancer